Lipirose-Gold 20 Capsule is a combination pharmaceutical formulation containing Aspirin (75 mg), Rosuvastatin (20 mg), and Clopidogrel (75 mg), designed to provide comprehensive cardiovascular protection. Aspirin, a well-known antiplatelet agent, inhibits cyclooxygenase enzymes, thereby reducing thromboxane A2 production and preventing platelet aggregation, which lowers the risk of arterial thrombosis. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively reduces low-density lipoprotein cholesterol (LDL-C) levels and exerts pleiotropic effects such as improving endothelial function and stabilizing atherosclerotic plaques. Clopidogrel, another antiplatelet agent, selectively inhibits the ADP receptor on platelet cell membranes, further preventing platelet activation and aggregation. The combined action of these agents is particularly beneficial in patients at high risk of cardiovascular events, including those with a history of myocardial infarction, stroke, or established peripheral arterial disease. Lipirose-Gold 20 Capsule is indicated for secondary prevention of atherothrombotic events and management of dyslipidemia in patients requiring dual antiplatelet therapy alongside lipid-lowering treatment. Usage should be under strict medical supervision due to potential risks such as bleeding, hepatic dysfunction, and drug interactions. Regular monitoring of liver function, lipid profile, and platelet activity is recommended during therapy.